BACKGROUND: One patient with B-cell Non-Hodgkin's Lymphoma developed severe hypomagnesaemia and tetany 15 days after the first course of treatment with ESHAP protocol. This prompted a careful look at the incidence and severity of hypomagnesaemia during treatment with this combination chemotherapy. METHOD: This patient and two further patients having the same treatment were monitored for hypomagnesaemia throughout their treatment period. RESULT: All three patients developed significant hypomagnesaemia requiring intravenous magnesium infusion in the second and third weeks after treatment though not after every course of chemotherapy. CONCLUSIONS: ESHAP protocol is often associated with significant hypomagnesaemia two to three weeks after treatment. Therefore, serum magnesium level should be monitored throughout the treatment period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC64621 | PMC |
| http://dx.doi.org/10.1186/1471-2326-2-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy.
J Clin Apher
February 2022
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Background: Performing stem cell collection after mobilization chemotherapy was a well-balanced strategy between anti-tumor effect and efficient collection of CD34+ cells, but deep and prolonged nadir exposed patients to risk of febrile neutropenia. Febrile neutropenia was known to be associated with lower yields of CD34+ cells, but quantitative data referring to association between yields of CD34+ cells and severity of neutropenia was lacking. We hypothesized that D-index, which was developed for quantitative evaluation of severity of neutropenia especially in the field of hematologic malignancies, could predict yields of CD34+ cells.
View Article and Find Full Text PDFRole of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Cancer Res Treat
January 2022
Division of Hematology-Oncology, Department of Internal Medicine, Biochemical Research Institution, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Purpose: There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective phosphodiesterase-4 inhibitor used for treating chronic obstructive pulmonary disease, is effective against B-cell malignancy via phosphoinositide 3-kinase (PI3K)-activity suppression. We analyzed the effects of roflumilast combined with ESHAP (etoposide, cisplatin, methylprednisolone, and cytarabine) chemotherapy in experimental and clinical settings.
View Article and Find Full Text PDFDT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Br J Haematol
February 2021
Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK.
There is no standard treatment for relapsed follicular lymphoma (FL). Although platinum-based combinations are one of the most used treatments, few data have been reported in this setting. Our aim was to analyse R-ESHAP efficacy in relapsed FL patients.
View Article and Find Full Text PDFEpstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation.
Ann Hematol
February 2020
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!